1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Dermatophytic Onychomycosis Market 2016-2020

Global Dermatophytic Onychomycosis Market 2016-2020

  • February 2016
  • -
  • Infiniti Research Limited
  • -
  • 57 pages

About Dermatophytic Onychomycosis

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

Technavio’s analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.


The market is divided into the following segments based on geography:
- APAC
- EMEA
- Americas

Technavio's report, Global Dermatophytic Onychomycosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- Anacor Pharmaceuticals
- Galderma
- Janssen Biotech
- Novartis
- Valeant Pharmaceuticals


Other prominent vendors
- Abeona Therapeutics
- Allergan
- Elorac
- GlaxoSmithKline
- Hexima
- Hisamitsu Pharmaceutical
- Mayne Pharma
- MediQuest Therapeutics
- Meiji Seika Pharma
- Merz Pharma
- Moberg Pharma
- NanoBio
- NovaBiotics
- Nuvo Research
- Pfizer
- Polichem
- Promius Pharma
- Sanofi
- Seren Pharmaceuticals
- Taro Pharmaceutical
- Topica Pharmaceuticals
- Viamet Pharmaceuticals

Market driver
- Increase in R&D
- For a full, detailed list, view our report

Market challenge
- Adverse effects and limited efficacy of drugs
- For a full, detailed list, view our report

Market trend
- Increased focus on combination therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Dermatophytic Onychomycosis Market 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Product offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
- Key buying criteria
PART 05: Overview: Dermatophytic onychomycosis
- Types of dermatophytic onychomycosis
- Risk factors
- Management
- Epidemiology
PART 06: Pipeline analysis
- TDT 067
- P-3058
- MOB-015
- VT-1161
- Luliconazole solution, 10%
- ME1111
- NP213
- HXP124
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by route of administration
- Topical
- Oral
PART 09: Geographical segmentation
- Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
- Dermatophytic onychomycosis market in Americas
- Dermatophytic onychomycosis market in EMEA
- Dermatophytic onychomycosis market in APAC
PART 10: Market drivers
- Increase in RandD
- Growing prevalence of dermatophytic onychomycosis
- Unmet medical needs
- Rise in prevalence of diabetes
PART 11: Impact of drivers
PART 12: Market challenges
- Adverse effects and limited efficacy of drugs
- Lack of awareness
- Increased availability of generics and alternative therapies
- Product recalls by US FDA
PART 13: Impact of drivers and challenges
PART 14: Market trends
- Increased focus on combination therapies
- Outsourcing of drugs manufacturing
- Increase in strategic alliances among vendors
- Incorporation of novel technology for product development
PART 15: Vendor landscape
- Competitive scenario
- Anacor Pharmaceuticals
- Galderma
- Janssen Biotech
- Novartis
- Valeant Pharmaceuticals
- Other prominent vendors
PART 16: Appendix
- List of abbreviations
PART 17: Explore Technavio



List of Exhibits
Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs
Exhibit 02: Percentage of population undergoing treatment globally 2015
Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis
Exhibit 04: Treatment algorithm for dermatophytic onychomycosis
Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview
Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Comparison of activity of topical medications for onychomycosis
Exhibit 09: Comparison of activity of oral medications for onychomycosis
Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015
Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: Anacor Pharmaceuticals: Key takeaways
Exhibit 22: Galderma: Key takeaways
Exhibit 23: Janssen Biotech: Key takeaways
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Valeant Pharmaceuticals: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.